Patents Represented by Attorney, Agent or Law Firm James J. Diehl
  • Patent number: 7432047
    Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.
    Type: Grant
    Filed: October 4, 2006
    Date of Patent: October 7, 2008
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
  • Patent number: 7425418
    Abstract: The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a retinoid X receptor as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.
    Type: Grant
    Filed: March 15, 2002
    Date of Patent: September 16, 2008
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Todd M. Kinsella, Esteban Masuda, Mark K. Bennett, Justin E. Warner, David C. Anderson
  • Patent number: 7423118
    Abstract: The present invention is directed to novel polypeptides, nucleic acids and related molecules which have an effect on or are related to the cell cycle. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided by the present invention are methods for identifying novel compositions which mediate cell cycle bioactivity, and the use of such compositions in diagnosis and treatment of disease.
    Type: Grant
    Filed: November 16, 2000
    Date of Patent: September 9, 2008
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Ying Luo, Xiang Xu, Cindy Leo, Betty Huang, Mary Shen
  • Patent number: 7422867
    Abstract: The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a CLLD8 protein as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.
    Type: Grant
    Filed: April 4, 2007
    Date of Patent: September 9, 2008
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Todd M. Kinsella, Justin E. Warner, Taisei Kinoshita, Mark K. Bennett, David C. Anderson
  • Patent number: 7420045
    Abstract: The present invention is directed to novel polypeptides, nucleic acids and related molecules which have an effect on or are related to the cell cycle. Also, provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided by the present invention are methods for identifying novel compositions which mediate cell cycle bioactivity, and the use of such compositions in diagnosis and treatment of disease.
    Type: Grant
    Filed: November 17, 2000
    Date of Patent: September 2, 2008
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Ying Luo, Xiang Xu, Cindy Leo, Betty Huang, Mary Shen
  • Patent number: 7378248
    Abstract: The present invention relates to methods and compositions utilizing inteins to generate libraries of cyclic peptides in vivo. The prevent invention also relates to methods for inhibiting protein-protein interaction.
    Type: Grant
    Filed: February 28, 2005
    Date of Patent: May 27, 2008
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: James B. Lorens, Todd R. Pray, Todd M. Kinsella, Mark K. Bennett
  • Patent number: 7378251
    Abstract: The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a thioredoxin-like 32 kDa protein (TXNL) as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.
    Type: Grant
    Filed: July 16, 2002
    Date of Patent: May 27, 2008
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Todd M. Kinsella, Justin E. Warner, Taisei Kinoshita, Mark K. Bennett, David C. Anderson
  • Patent number: 6833245
    Abstract: Methods and compositions for screening for transdominant effector peptides and RNA molecules selected inside living cells from randomized pools are provided.
    Type: Grant
    Filed: March 12, 2002
    Date of Patent: December 21, 2004
    Assignees: Rigel Pharmaceuticals, Inc., The Board of Trustees of the Leland Stanford Junior University
    Inventors: Garry P. Nolan, S. Michael Rothenberg
  • Patent number: 6824976
    Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: November 30, 2004
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
  • Patent number: 6808906
    Abstract: The present invention provides random cDNA expression vector libraries, comprising expression vectors which comprise random cDNAs positioned in sense orientation. Also provided are random cDNA expression vector libraries, comprising expression vectors which comprise random cDNAs positioned in antisense orientation. Methods for producing these libraries through directional cloning of random cDNAs are also provided. Also provided herein are methods of using these libraries to screen for agents capable of modulating cell phenotype in desirable ways.
    Type: Grant
    Filed: May 8, 2002
    Date of Patent: October 26, 2004
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Mary Shen, Simon Yu, Xian Wu, Donald Payan
  • Patent number: 6777179
    Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.
    Type: Grant
    Filed: March 27, 2002
    Date of Patent: August 17, 2004
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
  • Patent number: 6737241
    Abstract: Methods and compositions for screening for intracellular transdominant effector peptides and RNA molecules selected inside living cells from randomized pools are provided.
    Type: Grant
    Filed: July 27, 2001
    Date of Patent: May 18, 2004
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventor: Garry P. Nolan
  • Patent number: 6737240
    Abstract: The invention relates generally to methods of screening for drugs which bind to and/or regulate cellular proteins involved in drug resistance, particularly resistance of tumor cells to chemotherapeutic agents.
    Type: Grant
    Filed: May 24, 2000
    Date of Patent: May 18, 2004
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Ziang Xu, Donald Payan
  • Patent number: 6737232
    Abstract: The present invention is directed to novel polypeptides, nucleic acids and related molecules which have an effect on or are related to the cell cycle. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided by the present invention are methods for identifying novel compositions which mediate cell cycle bioactivity, and the use of such compositions in diagnosis and treatment of disease.
    Type: Grant
    Filed: November 17, 1999
    Date of Patent: May 18, 2004
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Ying Luo, Xiang Xu, Cindy Leo, Betty Huang, Mary Shen
  • Patent number: 6709814
    Abstract: The present invention is directed to compositions and methods including peptides which have a high affinity for each other and, when linked to a protein, are used to help fold the protein into a compact structure. By virtue of its stability and constraints, this scaffold can prolong the activity of any embedded protein sequences in the presence of cellular and other proteases. The compact structure can have other functional sequences embedded, and is preferable to linear and less constrained peptides for library screening, for creating structurally-biased peptide libraries and for targeting to specific intracellular and extracellular compartments. Compositions of the present invention can be displayed on the surface of viruses, archaebacteria, prokaryotic and eukaryotic cells for library screening, drug screening and display. Methods of the present invention are useful for screening in vivo for intracellular effector proteins modulating signaling pathways and to identify interacting proteins in vitro.
    Type: Grant
    Filed: April 2, 1999
    Date of Patent: March 23, 2004
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: David Anderson, Tarikere Gururaja
  • Patent number: 6667152
    Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.
    Type: Grant
    Filed: March 22, 2002
    Date of Patent: December 23, 2003
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
  • Patent number: 6623961
    Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.
    Type: Grant
    Filed: March 28, 2002
    Date of Patent: September 23, 2003
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
  • Patent number: 6589725
    Abstract: The present invention is directed to novel polypeptides, nucleic acids and related molecules which have an effect on or are related to the cell cycle. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided by the present invention are methods for identifying novel compositions which mediate cell cycle bioactivity, and the use of such compositions in diagnosis and treatment of disease.
    Type: Grant
    Filed: October 25, 1999
    Date of Patent: July 8, 2003
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Ying Luo, Eva Chan, Xiang Xu, Betty Huang
  • Patent number: 6579674
    Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.
    Type: Grant
    Filed: March 28, 2002
    Date of Patent: June 17, 2003
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell